Clinical Observation on effect of comprehensive immunotherapy in treating hepatic carcinoma after embolization chemotherapy

Wang Huaizhang

doi:10.1007/BF02934652

Your Location：

Home >

Browse articles >

Clinical Observation on effect of comprehensive immunotherapy in treating hepatic carcinoma after embolization chemotherapy

OriginalPaper | Updated：2021-08-27

- Clinical Observation on effect of comprehensive immunotherapy in treating hepatic carcinoma after embolization chemotherapy
- Clinical Observation on effect of comprehensive immunotherapy in treating hepatic carcinoma after embolization chemotherapy
- 中国结合医学杂志（英文版） 1999年5卷第2期页码：101-104
- Affiliations：
  
  Henan Provincial Tumor Hospital,Zhengzhou
- Author bio：
- Funds：
- DOI：10.1007/BF02934652
  中图分类号：
- 纸质出版日期：1999，
Scan for full text
Huaizhang, W. Clinical Observation on effect of comprehensive immunotherapy in treating hepatic carcinoma after embolization chemotherapy., CJIM 5, 101–104 (1999). https://doi.org/10.1007/BF02934652

Wang Huaizhang. Clinical Observation on effect of comprehensive immunotherapy in treating hepatic carcinoma after embolization chemotherapy[J]. Chinese Journal of Integrative Medicine, 1999,5(2):101-104.
Huaizhang, W. Clinical Observation on effect of comprehensive immunotherapy in treating hepatic carcinoma after embolization chemotherapy., CJIM 5, 101–104 (1999). https://doi.org/10.1007/BF02934652 DOI：

Wang Huaizhang. Clinical Observation on effect of comprehensive immunotherapy in treating hepatic carcinoma after embolization chemotherapy[J]. Chinese Journal of Integrative Medicine, 1999,5(2):101-104. DOI： 10.1007/BF02934652.

摘要

Objective: To probe the relationship between survival period and immune function of hepatic carcinoma patients after embolization chemotherapy.Methods: One hundred and eight patients of hepatocarcinoma were randomly divided into three groups. Group A was treated by embolization chemotherapy (ECT) alone

immunotherapy and Chinese herbal medicine were given to Group B and C respectively after ECT.Results: The short-term effective rate of Group A

B and C was 61.1%

83.3% and 80.6% respectively

the three-year survival rate 28.6%

39.1% and 47.3%

and the median survival time 11 months

17 months and 15 months respectively. Observation on immune function after treatment showed that patients who received ECT alone had a lower immunity while those who received immunotherapy or Chinese herbal medicine had a strengthened immunity.Conclusion: Survival period of hepatocarcinoma patients is related with their immune function

strengthening patients’ immunity could extend their survival period relatively.

Abstract

immunotherapy and Chinese herbal medicine were given to Group B and C respectively after ECT.Results: The short-term effective rate of Group A

B and C was 61.1%

83.3% and 80.6% respectively

the three-year survival rate 28.6%

39.1% and 47.3%

and the median survival time 11 months

strengthening patients’ immunity could extend their survival period relatively.

关键词

hepatocarcinomaembolization chemotherapyimmune function

Keywords

hepatocarcinomaembolization chemotherapyimmune function

references

1991: 2–12.

1 1990: 63–290.

48 1995; 29(12): 876–877.

1992; 11 (1): 38–41.

1993; 3(2): 113–115.

1995; 15(2): 102–104.

1991; 13(2): 157–158.

FULL TEXT LINK

More>

浏览量

354

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Carboxymethylpachymaran enhances immunologic function of dendritic cells cultured in two kinds of hepatoma carcinoma cell line’s supernatant via nuclear factor κB/Rel pathway

Fuzheng Yiliu Granule (扶正抑瘤颗粒) inhibits the growth of hepatocellular cancer by regulating immune function and inducing apoptosis in vivo and in vitro

Clinical observation on the endocrinal and immune functions in subjects with yin-deficiency constitution

Efficacy of auxiliary therapy with Danggui Buxue Decoction No.1 (当归补血汤1号) in treating patients of non-small cell lung cancer at peri-operational stage

Effect of TCM combined with chemotherapy on immune function and quality of life of patients with non-small cell lung cancer in stage III-IV